---
title: "Fresenius Kabi Oncology Ltd (FKONCO) — Share Price, Financials & Analysis"
symbol: "FKONCO"
company: "Fresenius Kabi Oncology Ltd"
canonical: "https://tapetide.com/stocks/FKONCO"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
generated_at: "2026-09-13T18:49:25.151Z"
---

# Fresenius Kabi Oncology Ltd (FKONCO)

Canonical page: https://tapetide.com/stocks/FKONCO

## Company

- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Face Value:** ₹1
- **F&O Eligible:** No
- **Website:** fresenius-kabi-oncology.com

## About

Fresenius Kabi Oncology Limited engages in the development, manufacture, and marketing of chemotherapeutic drugs for the treatment of cancer.

## Latest Price

## Key Insights

### Weaknesses

- Stock is trading at 5.15 times its book value
- The company has delivered a poor sales growth of 10.1% over past five years.
- Tax rate seems low
- Company has a low return on equity of 6.57% over last 3 years.
- Company might be capitalizing the interest cost

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| net income growth | 15% | 42% | 20% |
| revenue growth | -6% | 7% | 10% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2013 | Jun 2013 | Sep 2013 | Dec 2013 |
| --- | --- | --- | --- | --- |
| Sales | 93 | 127 | 96 | 85 |
| Expenses | 82 | 118 | 125 | 121 |
| Operating Profit | 11 | 8 | -29 | -37 |
| OPM % | 12 | 7 | -30 | -43 |
| Other Income | -6 | 1 | 0 | -6 |
| Interest | -2 | -5 | 7 | 10 |
| Depreciation | 7 | 7 | 8 | 8 |
| Profit before tax | 1 | 7 | -44 | -61 |
| Tax % | 962 | 32 | 2 | 4 |
| Net Profit | -8 | 5 | -45 | -64 |
| EPS in Rs | -0.49 | 0.3 | -2.83 | -4.02 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 411 | 413 | 527 | 596 | 408 | 464 | 542 | 624 | 703 | 660 |
| Expenses | 325 | 341 | 505 | 453 | 480 | 552 | 546 | 549 | 571 | 569 |
| Operating Profit | 87 | 71 | 22 | 143 | -72 | -88 | -5 | 75 | 132 | 90 |
| OPM % | 21 | 17 | 4.2 | 24 | -18 | -19 | -0.8 | 12 | 19 | 14 |
| Other Income | 31 | 34 | 91 | -5 | -8 | -34 | -13 | 13 | -13 | -60 |
| Interest | 19 | 18 | 18 | -3 | 13 | -13 | 29 | 37 | 46 | 37 |
| Depreciation | 13 | 17 | 24 | 26 | 31 | 44 | 52 | 49 | 55 | 55 |
| Profit before tax | 86 | 70 | 72 | 115 | -123 | -154 | -99 | 2 | 18 | -61 |
| Tax % | 7 | 30 | 29 | 30 | -10 | 2 | -17 | 213 | -6 | -12 |
| Net Profit | 80 | 49 | 51 | 81 | -111 | -157 | -83 | -2 | 20 | -54 |
| EPS in Rs | 5.07 | 3.11 | 3.22 | 5.09 | -7.04 | -9.93 | -5.22 | -0.15 | 1.24 | -3.41 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 16 | 16 | 16 | 16 | 16 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 476 | 526 | 577 | 657 | 546 | 505 | 424 | 421 | 441 | 390 |
| Borrowings | 269 | 333 | 147 | 140 | 311 | 349 | 421 | 521 | 474 | 463 |
| Other Liabilities | 150 | 185 | 181 | 226 | 226 | 245 | 317 | 260 | 298 | 360 |
| Total Liabilities | 912 | 1059 | 921 | 1039 | 1098 | 1116 | 1179 | 1219 | 1231 | 1229 |
| Fixed Assets | 195 | 258 | 305 | 352 | 463 | 483 | 522 | 494 | 469 | 456 |
| CWIP | 58 | 96 | 140 | 163 | 79 | 55 | 30 | 45 | 38 | 37 |
| Investments | 129 | 126 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 529 | 579 | 476 | 524 | 556 | 578 | 626 | 680 | 724 | 736 |
| Total Assets | 912 | 1059 | 921 | 1039 | 1098 | 1116 | 1179 | 1219 | 1231 | 1229 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 56 | 50 | 174 | 128 | -53 | -121 | 8 | -39 | 112 | 98 |
| Cash from Investing Activity | -63 | -116 | 17 | -121 | -86 | -44 | -40 | -29 | -30 | -52 |
| Cash from Financing Activity | 32 | 49 | -196 | -20 | 140 | 164 | -48 | 147 | -29 | -10 |
| Net Cash Flow | 26 | -16 | -5 | -13 | 1 | -1 | -79 | 79 | 53 | 36 |
| Free Cash Flow | -7 | -71 | 64 | 7 | -130 | -158 | -29 | -79 | 75 | 44 |
| CFO/OP | 78 | 92 | 856 | 109 | 57 | 137 | -180 | -52 | 89 | 113 |

### Ratios

| Item | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 134 | 156 | 140 | 113 | 100 | 93 | 90 | 83 | 84 | 83 |
| Inventory Days | 584 | 559 | 317 | 543 | 662 | 452 | 581 | 579 | 510 | 523 |
| Days Payable | 221 | 219 | 159 | 202 | 380 | 261 | 298 | 233 | 219 | 301 |
| Cash Conversion Cycle | 497 | 496 | 298 | 454 | 382 | 283 | 372 | 430 | 375 | 305 |
| Working Capital Days | 307 | 337 | 206 | 193 | 292 | 261 | 221 | 258 | 233 | 213 |
| ROCE % | 13 | 10 | 6 | 15 | -11 | -14 | -5 | 4 | 11 | 9 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 5 / 2 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 85.98 | Sell |
| EMA (10) | 85.01 | Sell |
| SMA (20) | 89.32 | Sell |
| EMA (20) | 88.5 | Sell |
| SMA (50) | 96.88 | Sell |
| EMA (50) | 95.73 | Sell |
| SMA (100) | 107.07 | Sell |
| EMA (100) | 103.67 | Sell |
| SMA (200) | 115.48 | Sell |
| EMA (200) | 112 | Sell |

### Oscillators — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 26.5 | Buy |
| MACD (12,26,9) | -4.36 | Sell |
| Stochastic (14,3,3) | 15.52 | Buy |
| ADX (14) | 41.33 | Buy |
| Williams %R (14) | -84.17 | Buy |
| ATR (14) | 5.14 | High Volatility |
| ROC (12) | -14.73 | Sell |
| Stoch RSI (14) | 0 | Buy |
| UO (7,14,28) | 40.58 | Neutral |

## Filings & Documents

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2011 from nse](https://archives.nseindia.com/annual_reports/AR_FKONCO_2010_2011_20062012121220.zip) |
| from nse | [Annual Report 2010 from nse](https://archives.nseindia.com/annual_reports/AR_FKONCO_2009_2010_18082010121500.zip) |
| from bse | [Annual Report 2013 from bse](https://www.bseindia.com/bseplus/AnnualReport/532545/5325450313.pdf) |
| from bse | [Annual Report 2012 from bse](https://www.bseindia.com/bseplus/AnnualReport/532545/5325450312.pdf) |
| from bse | [Annual Report 2011 from bse](https://www.bseindia.com/bseplus/AnnualReport/532545/5325450311.pdf) |
| from bse | [Annual Report 2010 from bse](https://www.bseindia.com/bseplus/AnnualReport/532545/5325450310.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:49:25.151Z.